Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Theratechnologies Inc. (THTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Theratechnologies's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.3200 +0.0200    +1.54%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
1.3169
-0.0031
-0.2349%
21:58:29 - Real-time Data
  • Volume: 12,885
  • Bid/Ask: 1.1000 / 1.3400
  • Day's Range: 1.3140 - 1.3656
Type:  Equity
Market:  United States
Theratechnologies 1.3200 +0.0200 +1.54%

Theratechnologies Company Profile

 
Read the Theratechnologies company profile to learn more about the business and the management team. View Theratechnologies Inc. facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

103

Equity Type

ORD

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Contact Information

Address 2015 Peel Street 11th Floor
Montreal, H3A 1T8
Canada
Phone 514 336 7800
Fax 514 331 9691

Top Executives

Name Age Since Title
Roger Guillemin - - Member of the Scientific Advisory Board
David Clemmons - - Member of the Scientific Advisory Board
Peter Reiss - - Member of the Scientific Advisory Board
Steven Grinspoon - - Member of the Scientific Advisory Board
Julian Falutz - - Member of the Scientific Advisory Board
George R. Merriam - - Member of the Scientific Advisory Board
Dawn A. Svoronos 70 2013 Independent Chair of the Board
Gerald A. Lacoste 79 2006 Independent Director
Paul Lévesque 59 2020 President, CEO & Director
Dale MacCandlish-Weil 67 2017 Independent Director
Joseph P. Arena 68 2021 Independent Director
Andrew T. Molson 55 2020 Independent Director
Frank A. Holler 67 2021 Independent Director
Jordan Zwick 37 2024 Independent Director
Elina Tea 47 2024 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TH Price Commentary

Write your thoughts about Theratechnologies Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email